Cancer Development Airway PI 3 K Pathway Activation Is an Early and Reversible Event in Lung

, 26ra25 (2010); 2 Sci Transl Med , et al. Adam M. Gustafson Cancer Development Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung http://stm.sciencemag.org/content/2/26/26ra25.full.html figures, can be found at: and other services, including high-resolution A complete electronic version of this article http://stm.sciencemag.org/content/suppl/2010/04/06/2.26.26ra25.DC2.html "Video Interview with Author" http://stm.sciencemag.org/content/suppl/2010/04/05/2.26.26ra25.DC1.html "Supplementary Material" can be found at: Supporting Online Material http://stm.sciencemag.org/content/2/26/26ra25.full.html#ref-list-1 , 27 of which can be accessed free: cites 55 articles This article http://www.sciencemag.org/about/permissions.dtl in whole or in part can be found at: reproduce this article permission to of this article or about obtaining reprints Information about obtaining

[1]  A. Fields,et al.  Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis. , 2009, Cancer research.

[2]  S. Lam,et al.  The Chemopreventive Agent Myoinositol Inhibits Akt and Extracellular Signal-Regulated Kinase in Bronchial Lesions from Heavy Smokers , 2009, Cancer Prevention Research.

[3]  Michael A Gorin,et al.  Protein kinase Cε: an oncogene and emerging tumor biomarker , 2009, Molecular Cancer.

[4]  Frank McCormick,et al.  EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma , 2009, Science Signaling.

[5]  Emmanuel Barillot,et al.  Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells , 2008, Breast Cancer Research.

[6]  L. Zhao,et al.  Class I PI3K in oncogenic cellular transformation , 2008, Oncogene.

[7]  Avrum Spira,et al.  A Prediction Model for Lung Cancer Diagnosis that Integrates Genomic and Clinical Features , 2008, Cancer Prevention Research.

[8]  R. Bernards,et al.  Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.

[9]  S. Wacholder,et al.  Gene Expression Signature of Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival , 2008, PloS one.

[10]  C. Eng,et al.  The nuclear affairs of PTEN , 2008, Journal of Cell Science.

[11]  Yoshihiro Yamanishi,et al.  KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..

[12]  Avrum Spira,et al.  Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression , 2007, Genome Biology.

[13]  A. Arcaro,et al.  Targeting mTOR signaling in lung cancer. , 2007, Critical reviews in oncology/hematology.

[14]  A. Arcaro,et al.  The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications , 2007, Current genomics.

[15]  T. Barrette,et al.  Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. , 2007, Neoplasia.

[16]  J. Minna,et al.  A Translational View of the Molecular Pathogenesis of Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  P. Sebastiani,et al.  Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer , 2007, Nature Medicine.

[18]  Fei Huang,et al.  Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.

[19]  J. Dering,et al.  Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.

[20]  Calum MacAulay,et al.  A Phase I Study of myo-Inositol for Lung Cancer Chemoprevention , 2006, Cancer Epidemiology Biomarkers & Prevention.

[21]  J. Baselga,et al.  Targeting Tyrosine Kinases in Cancer: The Second Wave , 2006, Science.

[22]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[23]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[24]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[25]  Mike West,et al.  Distinctions in the specificity of E2F function revealed by gene expression signatures. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Miyazawa,et al.  Telomerase expression in noncancerous bronchial epithelia is a possible marker of early development of lung cancer. , 2005, Cancer research.

[27]  J. Downward,et al.  Mechanisms of Disease: PI3K/AKT Signaling in Gastrointestinal Cancers , 2005, Zeitschrift fur Gastroenterologie.

[28]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Hartmann,et al.  Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers. , 2005, International journal of oncology.

[30]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[31]  M. Sajan,et al.  Atypical protein kinase C in insulin action and insulin resistance. , 2005, Biochemical Society transactions.

[32]  C. Mermel,et al.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Herman,et al.  Promoter Hypermethylation of Resected Bronchial Margins , 2004, Clinical Cancer Research.

[34]  Gang Liu,et al.  Effects of cigarette smoke on the human airway epithelial cell transcriptome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[36]  A. M. Riley,et al.  Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway , 2004, Oncogene.

[37]  M. West,et al.  Distinct gene expression phenotypes of cells lacking Rb and Rb family members. , 2003, Cancer research.

[38]  M. J. Fry,et al.  Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation , 2000, Oncogene.

[39]  C. Powell,et al.  Loss of heterozygosity in epithelial cells obtained by bronchial brushing: clinical utility in lung cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  S. Petersen,et al.  Distinct regions of allelic imbalance on chromosome 10q22-q26 in squamous cell carcinomas of the lung , 1998, Oncogene.

[41]  G. Mills,et al.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. , 1997, Cancer research.

[42]  Y. Miller,et al.  Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. , 1997, The Journal of clinical investigation.

[43]  J. Samet,et al.  Molecular damage in the bronchial epithelium of current and former smokers. , 1997, Journal of the National Cancer Institute.

[44]  S. Hecht,et al.  Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3' kinase. , 1997, Cancer research.

[45]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[46]  L. Cantley,et al.  Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation , 1985, Nature.

[47]  E. C. Hammond,et al.  Histologic changes in the larynx in relation to smoking habits , 1970, Cancer.

[48]  Y. Leea,et al.  Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target , 2006 .

[49]  Dong-Yingwu,et al.  Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions , 2005 .

[50]  Joel S. Parker,et al.  Adjustment of systematic microarray data biases , 2004, Bioinform..

[51]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[52]  M. West,et al.  Gene expression phenotypic models that predict the activity of oncogenic pathways , 2003, Nature Genetics.

[53]  P. R. Breggin.  The second wave. , 1973, Mental hygiene.